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Abstract 
Background: Bloodstream infections (BSI) remain a major cause of mortality in patients with malignancies. We pre‑
sent the first report on the microbiological profile of bacteraemia and fungaemia among cancer patients in Ghana.
Methods: From January 2010 through December 2013, we retrospectively analyzed the spectrum of bloodstream 
pathogens in cancer patients from Korle‑Bu Teaching Hospital, Ghana—focusing on multidrug resistant isolates 
(MDRs).
Results: Overall BSI were confirmed in 22 % (n = 93/453) of total blood cultures. Our data highlights a co‑dominance 
of Gram‑negative (n = 49/93, 52.6 %) and Gram‑positive (n = 40/93, 43.0 %) bacteria with the former less likely to 
infect children than adults [odds ratio (OR), 0.56; 95 % confidence interval (CI) 0.14–0.91; p value = 0.027]. Staphylo‑
coccus epidermidis was the most isolated bacteria (30.1 %; n = 28/93). About 61 % (n = 25/41) of Enterobacteriaceae 
isolates were resistant to cefotaxime; a majority (n = 24/25, 96 %) of which were MDRs and mostly susceptible to 
amikacin and levofloxacin. Four (80 %) penicillin resistant streptococci were found; 2 of which were MDRs and sensi‑
tive to erythromycin and cefuroxime. Methicillin resistant Staphylococcus aureus and vancomycin resistant enterococci 
were not identified. In multivariate analysis, the Enterobacteriaceae compared to other organisms were significantly 
associated with multidrug resistance (adjusted OR, 33.6; 95 % CI 6.41–88.73; p value 0.001).
Conclusion: MDRs, especially cefotaxime resistant Enterobacteriaceae, are common among patients with cancer in 
our institution but vary among different patient populations. The results show that empiric antibiotic treatment for 
cancer patients cannot be done effectively without regard for selective antimicrobial use based on local epidemio‑
logic data.
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Background
Bloodstream infections (BSI) remain a major cause of 
life-threatening complications in patients with cancer [1]; 
and are directly associated with prolonged hospital stay, 
high healthcare costs and increased risk of morbidity and 
mortality [2, 3]. Overall mortality rate as a result of BSI 
in cancer patients is reported at 25–32  % [1]. Bacteria 
are the most common cause [4–6]. Fungi have also been 
implicated as important aetiologic agents [7]. Surveil-
lance data worldwide on BSI in cancer patients remains 
limited, and is more so exemplified by the lack of data 
from Africa especially in western Africa [1, 8]. In Ghana, 
a wide range of bacterial isolates have been identified 
in infections at teaching and regional hospitals—with 
widespread prevalence of multidrug resistance among 
the various isolates [9, 10]. Although cancer patients are 
managed in our institution, there are no local data on the 
causes of BSI within this patient group. In order to adapt 
policies and encourage a more selective management 
strategy of cancer patients in Ghana, there is the need 
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for local monitoring of bacterial isolates and antibiogram 
[11, 12].
In this study, we retrospectively examined the micro-
biological profile of bacteraemia and fungaemia, over 
a 4-year period, in patients with malignancies in a ter-
tiary hospital setting in Ghana. There are relatively few 
microbiologic data on pediatric patients with malignan-
cies reported to date; and available studies on antibiotic 
resistance associated with cancer patients are often lim-
ited to particular antibiotics [13, 14] or to resistant organ-
isms, such as methicillin-resistant Staphylococcus aureus 
[15]. Therefore, our primary outcome was to evaluate the 
spectrum of bloodstream isolates and report on the anti-
microbial susceptibilities of causative pathogens in paedi-
atric and adult cancer patients, focusing on the presence 
of multidrug resistant phenotypes as a whole.
Methods
Study setting
This study was retrospectively conducted at the Korle-Bu 
Teaching Hospital (KBTH), which is a 2000-bed hospital 
in Ghana, West Africa. The hospital is the premier refer-
ral center in the country and covers all medical special-
ties. In this study, cancer patients with BSI were identified 
from the Microbiology Department of KBTH, which pro-
cesses over 40,000 clinical cultures annually. Three major 
units handle cancer patients in KBTH—haematology, 
paediatric oncology and the radio oncology unit.
Study design and sampling
Between January 2010 and December 2013, we retro-
spectively studied bloodstream isolates of cancer patients 
collected at the bacteriology unit of the Central Micro-
biology Laboratory in KBTH. Two sampling approaches 
were used. First, all isolates recovered from blood cul-
tures of cancer patients submitted to the microbiology 
laboratory of KBTH were characterized and analysed. 
Second, we reviewed laboratory records of all cancer 
patients with BSI. Blood culture isolates were selected 
on the following criteria: (1) confirmed as the causa-
tive agent of the infection for which blood cultures were 
performed, and (2) identified as first isolate per patient 
within the study period. Multiple isolates of the same 
bacteria per patient were only considered if antibiotic 
susceptibility patterns were different, and patients’ bacte-
raemia episodes were more than 2 months apart.
Culture and identification
For each patient, 1–3  mL (for paediatric patients) and 
8–10  mL (for adults) of blood cultures injected directly 
into Bactec® culture vials (Becton–Dickinson, USA) 
were submitted for laboratory diagnosis. Blood cultures 
were processed with Bactec® 9240 blood culture system 
(Becton–Dickinson, NJ, USA) according to manufac-
turer’s instructions. The presence of BSI was defined by 
at least one set of positive blood culture for bacteria or 
fungi in patients. When blood cultures yielded positive 
results, they were evaluated to determine whether it rep-
resented true bacteraemia, fungaemia, or simply contam-
ination. For potential skin contaminants (e.g., micrococci, 
Staphylococcus epidermidis), at least two separate posi-
tive blood cultures obtained from different sites had to 
be isolated for the results to be considered as true infec-
tion. A total of 111 blood cultures from cancer patients 
were positive for various organisms. Aerobic subcultures 
were made from positive culture vials onto blood, choco-
late, MacConkey and Saboraund agar. Identification of 
bacteria were carried out by Gram-stain microscopy and 
by conventional biochemical methods. Species identity 
were confirmed by the BBL crystal identification system 
(Becton–Dickinson, NJ, USA). Positive blood cultures for 
yeast and non-yeast fungi were identified on the basis of 
morphology.
Susceptibility testing
The susceptibilities of Gram-negative bacteria (GNB) 
to the antimicrobial agents ampicillin (10  µg) amoxi-
cillin/clavulanate (30  µg), cefuroxime (30  µg), cefo-
taxime (30  µg), chloramphenicol (30  µg), cotrimoxazole 
(25 µg), gentamicin (10 µg), amikacin (30 µg), ciprofloxa-
cin (5  µg), tetracycline (30  µg) and levofloxacin (5  µg) 
(HiMedia Laboratories, India) were determined with 
Kirby-Bauer disc diffusion method in accordance with 
the Clinical and Laboratory Standards Institute (CLSI) 
guidelines [16]. Erythromycin (30  µg), oxacillin (30  µg), 
and vancomycin (30  µg) were included for Gram posi-
tive bacteria (GPB). The reference strain E. coli ATCC 
25922 and Staphylococcus aureus ATCC 10221 were 
included as quality controls in the susceptibility assays. 
Relative to the panel of antibiotics tested for each iso-
late, and according to the international standard defini-
tions for acquired resistance, multidrug resistant (MDR) 
phenotype was defined as in  vitro non-susceptibility to 
≥1 agent in ≥3 antimicrobial categories [17]: penicillins, 
cephalosporins, beta-lactamase inhibitor combinations, 
fluoroquinolones, aminoglycosides, chloramphenicol, 
folate pathway inhibitors, tetracyclines, macrolides and 
glycopeptides.
Patients’ record review
To provide accurate information, patients and iso-
lates data were abstracted in the following two steps, 
(1) manual work through of laboratory records, and (2) 
physician-assisted medical reconciliation of laboratory 
data. Positive cultures were categorized into GNB and 
GPB. Data were retrospectively reviewed and compared. 
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Study data was compared between the following: cancer 
patients with Gram-positive BSI and those with Gram-
negative BSI; cancer patients with MDR BSI and those 
with non-MDR BSI; as well as study patients infected 
with cefotaxime resistant isolates and those with cefotax-
ime susceptible strains. Each patient was included only 
once for each outcome. Patients groups were compared 
regarding the following: demographics (age, gender), year 
of infection as well as assigned department of care. The 
data also included variables relating to infecting isolates, 
presence of febrile neutropenia, and cancer types. Paedi-
atric patients were defined as patients aged 0–13  years; 
adults were those >13 years old.
Statistics
Study data was captured into Microsoft Excel, and 
exported into Statistical Package for Social Sciences 
(SPSS, version 20.0) for editing and statistical analyses. 
Where appropriate, data were compared between two 
consecutive study periods (Period 1, 2010 through 2011; 
Period 2, 2012 through 2013) so that trends could be 
ascertained. Comparisons between categorical data were 
conducted with Fisher’s exact test or Chi-square with 
Marascuilo’s post hoc tests for multiple comparisons. 
Changes in incidence over time were analyzed by Chi-
square test for trend. Continuous variables are expressed 
as mean  ±  standard deviation. Normalized continuous 
data were compared using students’ t test with analyses 
of variance (ANOVA) for multiple comparisons. The 
Mann–Whitney U test was used for non-parametric 
continuous distributions. Point estimates of statistical 
significance were indicated with 2-tailed p values <0.05. 
Univariate analysis were computed with odds ratio (OR) 
with 95  % confidence interval (CI); variables with a p 
value <0.05 were analyzed in multivariate logistic regres-
sion models to identify independently associated predic-
tor variable(s). Predictive accuracy of the models was 
evaluated by Hosmer and Lemeshow goodness-of-fit test 
with p value >0.05 suggesting that the model predicts 
accurately on average.
Ethical considerations
The bacteriology unit the Microbiology Department of 
KBTH regularly de-identifies patients and their labo-
ratory records. The authors were not privy to patients’ 
laboratory data prior to anonymization. On receipt of 
de-identified patients’ laboratory data and isolates, we 
additionally anonymized all patients to ensure complete 
obscurity from laboratory archives. We further allotted 
arbitrary numbers to all isolates assigned to the study. 
Considering the anonymized data, as well as the retro-
spective nature of the study, we could not obtain patients’ 
consent for use of the laboratory records. Patients’ 
clinical notes were not reviewed for further information. 
Ethical approval for isolates and laboratory data was not 
required as the study was regarded as part of routine sur-
veillance measures for infection control.
Results
General characteristics
During the study period, and as part of patient manage-
ment, 23,708 blood cultures were submitted for micro-
biological investigations. Overall, 453 of the 23,708 
blood cultures were received from cancer patients from 
haematology, paediatric oncology and other allied units 
for laboratory investigations. Excluding negative results 
(n  =  341/453; 75.4  %) and contaminants [(n  =  18/453, 
3.9 %)—mostly Bacillus species (n = 9/18, 50 %)], a total 
of 93 episodes of BSI were observed (Table  1). From 
these, 18 (19.4  %) isolates were recovered in 2010, 29 
(31.1 %) in 2011, 31 (33.3 %) in 2012, and 11 (11.8 %) in 
2013. About 6.4 % (n = 11/93) of the BSI were polymicro-
bial—mostly Staphylococcus epidemidis plus Escherichia 
coli (63.6  %, n =  7/11). The median age was 34.0  years 
(range 1  year–78  years). More than 63  % (n  =  59/93) 
of cancer patients with BSI were children. Males com-
prised 60 % (n = 55/93) of the patients. Overall, 54.8 % 
(n = 54/93) of BSIs occurred in patients with hematolog-
ical malignancies.
Causative organisms
Of the 93 patients with bloodstream infections (Table 1), 40 
(43.0  %) had Gram positive bacteria (mostly Staphylococ-
cus epidermidis, n  =  28), 49 (52.6  %) had Gram-negative 
bacteria (Enterobacteriaceae, n = 32; Pseudomonas aerugi-
nosa, n = 10; Acinetobacter species, n = 7), and 4 (4.3 %) 
were fungi (all Candida species). Chi square trend for 
analysis showed that the proportions of GNB (p value for 
X2 trend = 0.504), GPB (p value for X2 trend = 0.896) and 
fungi (p value for X2 trend = 0.325) in BSI of cancer patients 
did not significantly change over the study period (Fig. 1).
Distribution of blood culture isolates
Table  2 shows the distribution of GPB and GNB across 
patients’ groups. Over the 4-year period, the proportion 
of blood cultures positive in adults (20.4 %; n = 34/167) 
and paediatric patients (21.5 %; n =  59/274) were simi-
lar (p value = 0.769). Also, the proportion of BSI due to 
GPB was greater (p value =  0.028) in children (52.5  %, 
n =  31/59) than in adults (26.5 %, n =  9/34). The GNB 
less often caused BSI in paediatric patients than adults 
(OR 0.56; 95 % CI 0.14–0.91; p value =  0.027). Overall, 
the proportion of BSIs between pediatric and adult popu-
lations did not differ for any bacterial species except E. 
coli which caused more (p value =  0.018) BSI in adults 
(n = 6/34, 17.6 %) than children (n = 2/59, 3.3 %). There 
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was no difference in the proportion of GPB or GNB 
between patients with haematologic cancers and those 
with non-haematologic malignancies.
Antibiotic susceptibility
In Table 3, differences in antibiogram between 49 Gram-
negative and 40 Gram-positive bacteria recovered from 
blood cultures of cancer patients are shown. Four (80 %) 
of the five GNB tested against amoxicillin/clavulanate 
were resistant and about one-half (excluding Pseu-
domonas species) were resistant to cefotaxime (60.9  %, 
n = 25/41). Greater than 60 % of the GNB were also sus-
ceptible to gentamicin (60.5 %, n = 24/39), ciprofloxacin 
(61.2  %, n  =  11/18) and amikacin (63.8  %, n  =  25/38). 
Overall, levofloxacin was the most effective antibiotic 
against GNB (76.5  %, n  =  13/17). Regarding GPB, few 
displayed resistance to gentamicin (16.7 %, n = 6/36) and 
ampicillin (27.7 %, n = 10/37). Most GPB were suscepti-
ble to erythromycin (91.2 %, n = 31/34) and vancomycin 
(87.5 %, n = 28/32).
Multidrug resistance
In this study, 44.9  % (n  =  40/89) of the bacterial iso-
lates recovered from blood cultures of cancer patients 
were multidrug resistant (Table  4). The MDR pheno-
types were significantly less in GPB (n =  6/40, 15.0  %) 
compared to GNB (n  =  34/49, 69.3  %). Focusing on 
specific MDR pathogens of worldwide interest, in  vitro 
non-susceptibility to cefotaxime (30  µg) was used as a 
presumptive screen positive test for third generation 
cephalosporin resistant Enterobacteriaceae [16]. About 
Table 1 Causative organisms of all episodes of bacteraemia compared by study periods
Numbers with differing superscripts and subscripts within columns and rows, respectively, are significantly different at the p < 0.05
X2 Chi‑square linear trend test with Mantel–Haenszel statistic, Period 1 first study period, Period 2 second study period
Isolates Period 1 Period 2 p value for  
X2 trend








Gram negatives (n = 49) a25 a11a a14a a24 a19a a5a 0.504
 Enterobacteriaceae (n = 32) 16 8a 8a 16 12a 4a 0.658
  Escherichia coli (n = 8) 5 3 2 3 1 2 0.469
  Klebsiella pneumoniae (n = 3) 0 0 0 3 3 0 0.442
  Citrobacter species (n = 12) 8 4 4 4 4 0 0.071
  Enterobacter species (n = 7) 1 0 1 6 4 2 0.058
  Providencia species (n = 1) 1 0 1 0 0 0 0.329
  Salmonella typhimurium (n = 1) 1 1 0 0 0 0 0.045
 Acinetobacter species (n = 7) 3 3 0 4 4 0 0.314
 Pseudomonas aeruginosa (n = 10) 6 0 6 4 3 1 0.896
Gram positives (n = 40) a22 b7a a15a 18a a12a a6a 0.896
  Enterococcus species (n = 2) 1 1 0 1 1 0 0.881
  Staphylococcus aureus (n = 4) 3 1 2 1 1 0 0.241
  Staphylococcus epidermidis (n = 28) 16 5 11 12 8 4 0.738
  Streptococcus species (n = 6) 2 0 2 4 2 2 0.184
Fungi (n = 4)





























Fig. 1 Aetiology of bloodstream infections in cancer patients at 
Korle‑Bu Teaching Hospital from 2010 to 2013. Differing superscripts 
within years are significantly different at the p value <0.05. No signifi‑
cant difference in prevalence of Gram‑positive, and Gram‑negative 
organisms was noted within the years of study. For each year, the 
number of fungi recovered was significantly (p value <0.05) less 
compared to Gram‑positive, and Gram‑negative bacteria. Changes in 
incidence of Gram negatives, Gram positives, or fungi over the 4‑year 
period were not significant (p value >0.05 for each group, Chi‑square 
for trend analysis)
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61  % (n  =  25/41) of Enterobacteriaceae isolates were 
cefotaxime resistant. A significant majority (n =  24/25, 
96 %) of these were MDRs. Among the Gram positives, 
multidrug resistant phenotypes were reported in Ente-
rococcus species (n = 1/2, 50 %), Staphylococcus aureus 
(n =  1/4, 25  %), Staphylococcus epidermidis (n =  2/28, 
25  %) and Streptococcus species (n  =  2/6, 33.3  %). All 
the MDR S. epidermidis were resistant to vancomycin 
but susceptible to erythromycin. This study did not iden-
tify any methicillin resistant S. aureus (based on oxacil-
lin susceptibility) or vancomycin resistant enterococci. 
Based on ampicillin resistance, four (80  %) penicillin 
resistant streptococci were found; 2 of which were van-
comycin resistant MDRs.
Characteristics of patients with MDR BSI
Table 5 shows the characteristics of cancer patients with 
BSI caused by MDR and non-MDR bacteria. Children 
were less likely to be infected with MDR organisms com-
pared to adults. Patients with haematologic malignan-
cies compared to those with non-haematologic cancers 
more frequently had MDR BSI. Compared to non-MDRs, 
MDR isolates were more frequently Enterobacteriaceae. 
In multivariate analysis, the Enterobacteriaceae com-
pared to other bacteria were significantly associated with 
MDR after adjusting for age, paediatric patients, cefotax-
ime resistance, Gram-negative bacteria and Pseudomon-
ads (adjusted odds ratio 33.6; 95 % CI 6.41–88.73; p value 
0.001).
Table 2 Distribution of blood culture isolates across patients’ groups
Numbers with differing superscripts within columns or differing subscripts within rows are significantly different at the p < 0.05
Paeds paediatric patients, Leuk. leukemia, Lymph. lymphoma, Myel myeloma, Non-haematol. non‑haematologic malignancies (type not confirmed)














Gram negatives (n = 49) a26 a23 0.028 a22 (62.8)a a9 (60.0)a a2 (50.0)a a16 (41.0)a 0.056 a9
 Enterobacteriaceae 
(n = 32)
16 16 0.051 15 8 1 12 0.182 6
  Escherichia coli 
(n = 8)
2 6 0.018 5 0a 1 2 0.310 1
  K. pneumoniae 
(n = 3)
2 1 0.906 1 0 0 2 0.378 2
  Citrobacter species 
(n = 12)
6 6 0.300 6 2 0a 4 0.517 1
  Enterobacter species 
(n = 7)
5 2 0.648 2 2 0 3 0.959 2
  Providencia species 
(n = 1)
1 0 0.455 0 1 0 0 0.393 0
  Salmonella typhimu‑
rium (n = 1)
1 0 0.455 0 0 0 1 0.236 0
 Acinetobacter species 
(n = 7)
5 2 0.648 1 3 1 2 0.456 2
 Pseudomonas aerugi-
nosa (n = 10)
5 5 0.350 7 1 0 2 0.137 1
Gram positives (n = 40) a31 b9 0.014 b10 (28.5)a a6 (40.0)a a2 (50.0)a a21 (53.8)a 0.048 a12
  Enterococcus species 
(n = 2)
2 0 0.278 0 0 0 2 0.093 1
  Staphylococcus 
aureus (n = 4)
3 1 0.623 0 1 1 2 0.738 0
  Staphylococcus epi-
dermidis (n = 28)
21 7 0.128 10 2 0 15 0.088 9
  Streptococcus spe‑
cies (n = 6)
5 1 0.295 0 3 1 2 0.659 2
Fungi (n = 4)
  Candida species b2 c2 0.568 2 (5.7)c b0 a0 b2 (5.3) 0.738 b2
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Discussion
To our knowledge, this is the first study conducted in 
Ghana to document the microbiological features of 
bacteraemia among oncology patients. This retrospec-
tive study disclosed several important findings. Blood 
stream infections accounted for 93 of 453 blood cul-
tures from cancer patients. Three observations merit 
attention. First, Staphylococcus epidermidis was the most 
frequently isolated organism (n  =  28/93, 30.1  %) at an 
average rate of 7 isolates per year. Second, the frequen-
cies of BSI pathogens during the entire period of observa-
tion from 2010 through 2013 did not change significantly. 
Infections by GNB have predominated in such cancer 
patients in several reported studies with comparable 
Table 3 Antibiotic susceptibility of blood culture isolates from cancer patients at KBTH
Numbers with differing superscripts between Gram‑positives and Gram negatives within an antimicrobial agent are significantly different at the p < 0.05
AMP ampicillin, CRX cefuroxime, AUG amoxicillin/clavulanate, GEN gentamicin, AMK amikacin, CIP ciprofloxacin, LEV levofloxacin, COT cotrimoxazole, TET tetracycline, 
CTX cefotaxime, CHL chloramphenicol
Microorgan-
isms
Resistance to antimicrobial agents (%)






























3/4 (75.0) 9/24 (42.8) 9/31 (29.0) 7/11 
(63.6)












4/5 (80.0) 1/1 (100) 3/8 (37.5) 4/7 (57.1) 4/5 (80.0) 0/2 (0.0) 6/6 (100) 5/6 (83.3) 4/8 (50.0) 6/6 (100)





2/3 (66.7) – 2/3 (66.7) 0/3 (0.0) 1/1 (100) 0/1 (0.0) 3/3 (100) 3/3 (100) 3/3 (100) 3/3 (100)





9/12 (75.0) 0/1 (0.0) 4/12 (33.3) 3/12 (25.0) 0/1 (0.0) 1/3 (33.3) 8/11 (72.7) 10/10 
(100)







7/7 (100.0) 2/2 (100.0) – 2/7 (28.7) 2/4 (50.0) 1/2 (50.0) 6/6 (100) 5/5 (100) 6/7 (85.7) 4/4 (100)
  Providencia 
species 
(n = 1)
1/1 (100) 0/1 (0.0) – 0/1 (0.0) 0/1 (0.0) – – 1/1 (100) – 0/1 (0.0) –















– – – 0/8 (0.0) – 0/6 (0.0) 0/6 (0.0) – – – –
AMP CRX AUG GEN ERY CLO VAN COT TET
Gram positives (n = 40) b10/37 (27.7) b10/39 (25.6) a2/3 (66.7) b6/36 (16.7) 3/34 (8.8) 0/4 (0.0) 4/32 (12.5) b2/12 (16.6) b2/5 (40.0)
  Enterococcus species 
(n = 2)
1/1 (100.0) 1/1 (100.0) – 2/2 (100.0) 1/1 (100) – 0/1 (0.0) – 0/1 (0.0)
  Staphylococcus aureus 
(n = 4)
3/3 (100.0) 2/4 (50.0) 0/1 (0.0) 0/4 (0.0) 1/3 (33.3) 0/4 (0.0) 0/1 (0.0) 1/1 (100) 2/3 (66.7)
  Staphylococcus epidermidis 
(n = 28)
2/28 (7.1) 2/28 (7.1) – 2/28 (7.1) 1/28 (3.5) – 2/28 (7.1) 1/10 (10.0) 0/1 (0.0)
  Streptococcus species 
(n = 6)
4/5 (80.0) 5/6 (83.3) 2/2 (100) 2/2 (100.0) 0/2 (0.0) – 2/2 (100) – –
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patient populations [18–20]. However, the aetiology of 
BSI in cancer patients is dramatically changing with clear 
shifts in infecting organisms; so that now BSI with sin-
gle pathogens are due largely to Gram-positive cocci [1, 
7, 21]. There are no previous surveys in Ghana to com-
pare our data; and the reasons why GPB and GNB are 
dominant in our institution over the last 4 years remain 
unknown. Last, about 60 % of the Entrobacteriaceae were 
cefotaxime resistant. We are unable to determine if the 
isolates were positive for beta-lactamases, which lim-
its the scope for comparing results from this study with 
existing literature. However, given that the variety of class 
C cephalosporinases (AmpCs) and extended spectrum 
beta-lactamases (ESBLs) constitute the predominant 
mechanisms for cephalosporin resistant worldwide [9, 
10, 22], the high levels of cefotaxime-resistance observed 
in our study may be compatible with findings from other 
works in Ghana reporting high prevalence of ESBLs 
(>45 %) in the family Enterobacteriaceae [9, 23]. Carbap-
enems are often the treatment of choice for AmpC and 
ESBL-producing organisms. However, susceptibility data 
to carbapenems were unavailable; and we are unable to 
determine if cefotaxime-resistant Enterobacteriaceae 
reported in this study comprised isolates resistant to 
carbapenems.
Amoxicilin plus clavulanic acid, cefotaxime, gen-
tamicin and ciprofloxacin are the predominant empiric 
therapies for treatment of blood stream infections in 
Ghana. Hovewer, the general antibiogram of the GNB 
and GPB revealed an overall high resistance to many of 
the routinely used drugs. It is the experience in KBTH 
that resistance to many routinely used antibiotics is high; 
and the prevalence is rising [9, 10]. We therefore believe 
that the choice of empiric therapy should vary according 
to locally prevalent isolates and their resistance patterns. 
Currently, use of cefotaxime or amoxicillin plus clavu-
lanic acid as empirical monotherapy for febrile illness 
in cancer patients across most centers may not be justi-
fied due to the high levels of in vitro resistance observed 
against these drugs. Amikacin and levofloxacin were the 
most active antibiotics against GNB; and represent bet-
ter alternatives over gentamicin and ciprofloxacin. Levo-
floxacin and amikacin have been on the Ghanaian market 
for a relatively short period of time since 2002; amika-
cin is parenteral and less likely to be misused or abused. 
Moreover, these antibiotics are expensive and usually 
prescribed for more serious infections, although systemic 
therapy over a period may also favour the selection of 
levofloxacin or amikacin resistant strains. In this study, 
Staphylococcus aureus remained fully susceptible to oxa-
cillin, reflecting the low prevalence of methicillin-resist-
ant staphylococci recently noted in KBTH [24]. Also, 
Staphylococcus epidermidis were the predomiant organ-
isms, and exhibited high susceptibility to ampicillin. 
Table 4 Multiple drug resistant strains recovered from blood cultures of cancer patients
Numbers with differing superscripts within antimicrobial agent are significantly different at the p < 0.05
CTX-R cefotaxime (30 μg) resistant, CTX-S cefotaxime susceptible, Period 1 first study period, Period 2 second study period
Microorganism Multiple drug resistant isolates (%)
Total Period 1 Period 2
Number CTX-R CTX-S p value Number CTX-R CTX-S p value
Gram negatives (n = 49) a34/49 (69.3) a15/25a (60.0) 9/15 6/15 0.273 a19/24a (79.2) 16/19 3/19 <0.001
 Enterobacteriaceae (n = 32) 28/32 (87.5) 12/16a (75.0) 7/12 5/12 0.414 16/16b (100.0) 13/16 3/16 <0.001
  Escherichia coli (n = 8) 8/8 (100) 5/5a (100) 3/5 2/5 0.527 3/3a (100) 1/3 2/3 0.414
  K. pneumoniae (n = 3) 3/3 (100) 0 0 0 – 3/3 (100) 3/3 0/3 0.014
  Citrobacter species (n = 12) 9/12 (75.0) 5/8a (62.5) 3/5 2/5 0.527 4/4a (100) 4/4 0/4 0.004
  Enterobacter species (n = 7) 7/7 (100) 1/1a (100) 1/1 0/1 – 5/6a (100) 5/6 0/6 <0.001
  Providencia species (n = 1) 0/1 (0.0) 0/1 0 0 – 0 0 0 –
  Salmonella typhimurium (n = 1) 1/1 (100) 1/1 (100) 0/1 1/1 – 0 0 0 –
 Acinetobacter species (n = 7) 6/7 (85.7) 3/3a (100) 2/3 1/3 0.414 3/4a (75) 3/4 0/4 0.028
 Pseudomonas aeruginosa (n = 10) 0/10 (0.0) 0/6a (0.0) – – 0/4a (0.0) – –
Gram positives (n = 40) b6/40 (15.0) b1/22a (4.5) – – b5/18b – –
  Enterococcus species (n = 2) 1/2 (50.0) 1/1a (50.0) – – 0/1a (0.0) – –
  Staphylococcus aureus (n = 4) 1/4 (25.0) 0/3a (0.0) – – 1/1a (100) – –
  Staphylococcus epidermidis 
(n = 28)
2/28 (7.2) 0/16a (0.0) – – 2/12a (16.7) – –
  Streptococcus species (n = 6) 2/6 (33.3) 1/2a (50.0) – – 1/4a (25.0) – –
Total 39/89 (43.9) 16/47a (34.1) 23/42b (54.7)
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Table 5 Differences in BSI caused by Gram positive and Gram negative bacteria, and between MDRs and non-MDRs
Odds ratio in multivariate analysis were adjusted for age, paediatric patients, cefotaxime resistance, Gram‑negative bacteria, Enterobacteriaceae and Pseudomonads
MDRs multidrug resistant strains, CI confidence interval, SD standard deviation, CTX cefotaxime










  Yes 55 23 32 0.72 (0.31–1.69) 0.450 
  No 34 17 17
 Age (± SD) 24.05 ± 2.41 31.09 ± 3.32 0.21 (0.19–0.79) <0.001
 Paediatric patients
  Yes 58 20 38 0.29 (0.11–0.72) 0.007 
  No 31 20 11
 Cancer type
  Leukemia 32 14 18 0.93 (0.9–2.21) 0.862
  Lymphoma 15 7 8 1.08 (0.35–3.30) 0.887
  Myeloma 4 1 3 0.39 (0.04–3.93) 0.624
  Solid cancer 10 4 6 0.79 (0.21–3.04) 1
  Undiagnosed 26 12 14 1.07 (0.43–2.68) 0.887
 Haematologic cancers
  Yes 31 23 3.89 (1.53–9.86) 0.003 
  No 9 26
 Febrile neutropenia 21 10 11 1.15 (0.43–3.07) 0.778
 Others 68 30 38
 Year of infection
  2010 18 8 10 0.97 (0.34–2.76) 1
  2011 29 16 15 1.51 (0.63–3.63) 0.353
  2012 31 17 14 1.84 (0.76–4.46) 0.17
  2013 11 5 6 1.02 (0.29–3.63) 1
 Patient location
  Child health 46 20 26 0.86 (0.38–2.04) 0.778
  Haematology 25 12 13 1.18 (0.47–2.99) 0.718
  Others 15 7 8 1.08 (0.36–3.31) 0.887
 CTX resistance 0.001
  Yes 40 26 14 4.64 (1.89–11.39)
  No 49 14 35
 Gram negatives
  Yes 49 34 15 12.8 (4.45–37.05) <0.001 
  No 40 6 34
 Enterobactericeae
  Yes 32 28 4 26.2 (7.70–89.44) <0.001 
  No 57 12 45
 Pseudomonads
  Yes 10 0 10 – 0.004 
  No 79 40 39
 Multivariate factor(s)
Enterobacteriaceae 33.6 (6.41–88.73) <0.001
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Given the low levels of polymicrobial infections, and the 
dual dominance of BSI by GPB and GNB, perhaps the 
combination therapy of amikacin plus a penicillinase sta-
ble penicillin such as cloxacillin would offer good empiri-
cal coverage across the different bacteria groups.
Multidrug resistant phenotypes accounted for 15.0  % 
(n = 6/40) of Gram-positive organisms, and were mostly 
vancomycin-resistant Staphylococcus epidermidis 
(n = 2/6) and vancomycin-resistant Streptococcus species 
(n  =  2/6). Our concern regarding the MDR isolates of 
GPB is twofold. To begin with, S. epidermidis and other 
coagulase-negative staphylococci isolated from blood 
cultures were previously often considered contaminants. 
In this study, S. epidermidis was the leading cause of BSI 
in both adults and paediatric cancer patients. Second, the 
presence of S. epidermidis resistant to vancomycin is also 
worrying. The occurrence of MDR vancomycin-resistant 
S. epidermidis and Streptococcus species, although rare, 
presupposes that vancomycin may not be a completely 
reliable antibiotic in the empiric treatment of infections 
due to Gram positive cocci, and underpins the impor-
tance of routine antibiogram to the management of infec-
tions in our institution.
We evaluated patient characteristics associated with 
aetiology of BSI infections in cancer patients. Notably, 
paediatric cancer patients were less often infected with 
Gram-negative organisms. Our results are consistent 
with previously demonstrated findings in which Gram-
positive cocci were the predominant cause of BSI in pedi-
atric cancer patients in Groningen and Amsterdam (the 
Netherlands) and in Bern (Switzerland) [21]. Similarly, 
in a previous report from the National Cancer Institute 
at Cairo University, Gram-positive cocci were found to 
account for 61.9  % of the total isolates from paediatric 
cancer patients [25]. Recently, many workers have indi-
cated that the prominence of Gram-positive organisms in 
paediatric cancer patients may reflect a more widespread 
chemotherapy-induced mucositis and the presence of 
indwelling intravascular devices [7, 26, 27].
There are some potential limitations of this study that 
should be discussed briefly. Blood stream infections in 
cancer patients over the 4-years were identified as includ-
ing 453 patients. Whereas the limited number may reflect 
the relative incidence of organisms in a Ghanaian tertiary 
care setting biased by its referral policies, it also high-
lights a decline in the availability of patients’ specimens 
for institutional research and public health surveillance 
due to a marked increase in commercial microbiology 
test services. Note also that by being retrospective, sus-
ceptibility testing on all isolates were not available for 
many of the antibiotics. Also patients had been stratified 
with predetermined definitions to which we were unable 
to fully assess clinical history for correlations that might 
contribute to risk factor analysis. It is worth noting that 
oxacillin susceptibility (rather than cefoxitin) was used in 
reporting MRSAs [16]. The occurrence of MRSAs in this 
study may therefore be underestimated. Despite these 
shortcomings, our findings offer information that should 
help to inform the suitability of local policies in manag-
ing BSI in cancer patients.
In conclusion, our data highlights a current trend of 
GNB/GPB duoplay in BSI with a clear stratification of 
risk factors for aetiologic agents—whereas paediatric 
patients were at increased risk of Gram positive bacterae-
mia, adults were significantly associated with Gram-neg-
ative organisms with considerable multidrug resistance 
phenotypes among Enterobacteriaceae. Adapting selec-
tive antimicrobial use based on local epidemiologic data 
will maximize clinical outcome of empiric antibiotic ther-
apy among cancer patients in our institution. Our find-
ings should compel a concerted effort in our institution 
and elsewhere for local monitoring of bacterial isolates in 
order to adapt policies on antibiotic therapy based on the 
local antibiotic susceptibility profiles.
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